» Articles » PMID: 24941021

Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency

Abstract

Little is known about the genetic factors that contribute to familial colorectal cancer type X (FCCX), characterized by hereditary nonpolyposis colorectal carcinoma with no mismatch repair defects. Genetic linkage analysis, exome sequencing, tumor studies, and functional investigations of 4 generations of a FCCX family led to the identification of a truncating germline mutation in RPS20, which encodes a component (S20) of the small ribosomal subunit and is a new colon cancer predisposition gene. The mutation was associated with a defect in pre-ribosomal RNA maturation. Our findings show that mutations in a gene encoding a ribosomal protein can predispose individuals to microsatellite-stable colon cancer. Evaluation of additional FCCX families for mutations in RPS20 and other ribosome-associated genes is warranted.

Citing Articles

New RPS20 gene variant in colorectal cancer diagnosis: insight from a large series of patients.

Amiot J, Gubeljak L, Fontaine A, Smith D, Mortemousque I, Parodi N Fam Cancer. 2025; 24(1):22.

PMID: 39920491 DOI: 10.1007/s10689-025-00446-y.


Genetics, diet, microbiota, and metabolome: partners in crime for colon carcinogenesis.

La Vecchia M, Sala G, Sculco M, Aspesi A, Dianzani I Clin Exp Med. 2024; 24(1):248.

PMID: 39470880 PMC: 11522171. DOI: 10.1007/s10238-024-01505-x.


Clinical significance of ribosomal protein S15 expression in patients with colorectal cancer liver metastases.

Sakano Y, Matoba D, Noda T, Kobayashi S, Yamada D, Tomimaru Y J Hepatobiliary Pancreat Sci. 2024; 31(9):611-624.

PMID: 38838053 PMC: 11503462. DOI: 10.1002/jhbp.12012.


Germline NPAT inactivating variants as cause of hereditary colorectal cancer.

Terradas M, Schubert S, Viana-Errasti J, Ruano D, Aiza G, Nielsen M Eur J Hum Genet. 2024; 32(7):871-875.

PMID: 38778081 PMC: 11219789. DOI: 10.1038/s41431-024-01625-8.


Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment.

Wang M, Vulcano S, Xu C, Xie R, Peng W, Wang J J Pharm Anal. 2024; 14(3):308-320.

PMID: 38618250 PMC: 11010632. DOI: 10.1016/j.jpha.2023.10.001.


References
1.
Nieminen T, Abdel-Rahman W, Ristimaki A, Lappalainen M, Lahermo P, Mecklin J . BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology. 2011; 141(1):e23-6. DOI: 10.1053/j.gastro.2011.03.063. View

2.
Chomczynski P . A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993; 15(3):532-4, 536-7. View

3.
Gazda H, Preti M, Sheen M, ODonohue M, Vlachos A, Davies S . Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Hum Mutat. 2012; 33(7):1037-44. PMC: 3370062. DOI: 10.1002/humu.22081. View

4.
Huang J, Kuismanen S, Liu T, Chadwick R, Johnson C, Stevens M . MSH6 and MSH3 are rarely involved in genetic predisposition to nonpolypotic colon cancer. Cancer Res. 2001; 61(4):1619-23. View

5.
Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M . Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med. 2013; 369(26):2504-14. DOI: 10.1056/NEJMoa1309199. View